Amgen files update to Tavneos label as FDA escalates push to withdraw
Nicole DeFeudis / endpoints - Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA. The company filed a supplement on Wednesday that would add more information to the warning ...
AI Summary: Regulators have intensified scrutiny of Amgen’s Tavneos, weighing withdrawal amid safety and efficacy concerns. Amgen responded by filing a label update as the agency evaluates next steps, setting up a regulatory standoff that could alter patient access and the drug’s commercial fate while investigators review supporting trial data.
Related Stories
US gray‑market peptides face scrutiny as FDA panel debate looms / 6 days
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 7 wks
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 3 months
Denali drug receives accelerated approval for rare CNS indication / 3 months
FDA again rejects Aldeyra’s dry‑eye drug for weak evidence / 3 months
FDA launches bonus pilot to speed up drug reviewer throughput / 4 months
FDA launches individualized therapy framework for ultra-rare diseases / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pediatric Oncology, Healthcare, CDC, Gene Therapy and look for the RSS link.
StackHealth Time Machine